CHICAGO: A Phase III trial of Pfizer Inc's drug Ibrance showed that, in combination with hormone therapy, the drug more than doubled the duration of disease control for women with the most common type of breast cancer. At the time of an interim analysis, patients given Ibrance in combination with AstraZeneca Plc's Faslodex , a widely used treatment to block estrogen, lived an average of 9.2 months before their cancer worsened.